利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

40 条记录 (耗时 0.029 秒)

    Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
    3.
    发明申请
    Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders 有权
    用于治疗阿尔茨海默病和其他β-淀粉样蛋白原纤维发生障碍的小肽

    公开(公告)号：US20050244334A1

    公开(公告)日：2005-11-03

    申请号：US11016706

    申请日：2004-12-16

    申请人： Gerardo Castillo ,  Thomas Lake ,  Beth Nguyen ,  Virginia Sanders ,  Alan Snow

    发明人： Gerardo Castillo ,  Thomas Lake ,  Beth Nguyen ,  Virginia Sanders ,  Alan Snow

    IPC分类号： A61K38/08 ,  A61K38/10 ,  A61K51/00

    CPC分类号： A61K38/08 ,  A61K38/10 ,  C07K7/08 ,  G01N33/6896 ,  G01N2800/2821

    摘要： A pharmaceutical composition that includes a peptide of formula Y-(X-aa)-Z. (X-aa) is generally an amino acid sequence selected from -Arg-Val-Ser-Val-Arg-Trp-, -Arg-Val-Ala-Val-Ile-, -His-Gly-Arg-Leu-Val-Phe-, -Leu-Ala-Phe-Val-Leu-Arg-, and -Thr-Leu-Phe-Leu-Ala-Arg-. And Y is generally an amino terminal modifying group selected from an amino acid, a N-acylated amino acid, a peptide, a N-acylated peptide, and hydrogen. And Z- is carboxyl-terminal modifying group selected from hydrogen, an amino acid, a C-amidated amino acid, a peptide, a C-amidated peptide, or an amide or hydroxyl group such as an alkyl amide, an aryl amide, or an alcohol. A composition of matter that includes at least one of the peptide sequences -Arg-Val-Ala-Val-Ile-, -Leu-Ala-Phe-Val-Leu-Arg-, -Thr-Leu-Phe-Leu-Ala-Arg-, -Arg-Val-Ser-Val-Arg-Trp-, -His-Gly-Arg-Leu-Val-Phe-. Preferably at least one amino acid of the peptide sequence is a D-amino acid.

    摘要翻译： 一种药物组合物，其包含式Y-（X-aa）-Z的肽。 （X-aa）通常是选自-Arg-Val-Ser-Val-Arg-Trp-，-Arg-Val-Ala-Val-Ile-，-His-Gly-Arg-Leu-Val- Phe-，-Leu-Ala-Phe-Val-Leu-Arg-和-Thr-Leu-Phe-Leu-Ala-Arg-。 Y通常是选自氨基酸，N-酰化氨基酸，肽，N-酰化肽和氢的氨基末端修饰基团。 Z-是选自氢，氨基酸，C-酰胺化氨基酸，肽，C-酰胺化肽或酰胺或羟基的羧基末端修饰基团，例如烷基酰胺，芳基酰胺或 一个酒精。 包含至少一个肽序列-Arg-Val-Ala-Val-Ile-，-Leu-Ala-Phe-Val-Leu-Arg-，-Thr-Leu-Phe-Leu-Ala- Arg-，-Arg-Val-Ser-Val-Arg-Trp-，-His-Gly-Arg-Leu-Val-Phe-。 优选地，肽序列的至少一个氨基酸是D-氨基酸。

    Rapid induction of Alzheimer's amyloid plaque formation by sulfated glycosaminoglycans
    4.
    发明申请
    Rapid induction of Alzheimer's amyloid plaque formation by sulfated glycosaminoglycans 审中-公开
    通过硫酸化糖胺聚糖快速诱导阿尔茨海默氏淀粉样斑块形成

    公开(公告)号：US20080044917A1

    公开(公告)日：2008-02-21

    申请号：US11487149

    申请日：2006-07-14

    申请人： Beth Nguyen ,  Paula Choi ,  Virginia Sanders ,  Gerardo Castillo ,  Alan Snow

    发明人： Beth Nguyen ,  Paula Choi ,  Virginia Sanders ,  Gerardo Castillo ,  Alan Snow

    IPC分类号： G01N33/00

    CPC分类号： G01N33/6896 ,  G01N2400/40 ,  G01N2500/00 ,  Y10T436/143333

    摘要： A method of induction of amyloid plaques includes immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) on a selected medium and adding to the immobilized SGAG on the medium a quantity of dissolved low fibrillar Aβ 1-40 (LFAβ). The LFAβ is added preferably in a Aβ:SGAG w/w ratio of about 1:1. SGAGs are preferably selected from heparin, heparan sulfate, keratan sulfate, dermatan sulfate, chondroitin-4-sulfate and chondroitin-6-sulfate. Screening methods and kits for screening either immobilize a quantity of a selected sulfated glycosaminoglycan (SGAG) on a selected medium, followed by adding to a quantity of dissolved low fibrillar Aβ 1-40 (LFAβ) a selected quantity of the selected amyloid therapeutic candidate to create a test solution, and then adding to the immobilized SGAG on the medium a selected quantity of the test solution to test for inhibition, or preform amyloid plaques on the medium by immobilizing a quantity of a selected sulfated glycosaminoglycan (SGAG) or a GAG-related macromolecule on a selected medium and then adding a selected quantity of dissolved low fibrillar Aβ 1-40 (LFAβ), followed by adding to the amyloid plaques on the medium a selected quantity of a test solution of a selected amyloid therapeutic candidate to test for disruption.

    摘要翻译： 诱导淀粉样蛋白斑块的方法包括将一定数量的选择的硫酸葡糖胺聚糖（SGAG）固定在选定的培养基上，并向培养基上的固定化SGAG加入一定量的溶解的低纤维Aβ1-40（LFAbeta）。 LFAbeta优选以约1:1的Abeta：SGAG w / w比添加。 SGAG优选选自肝素，硫酸乙酰肝素，硫酸角质素，硫酸皮肤素，硫酸软骨素-4-硫酸盐和硫酸软骨素-6-硫酸盐。 用于筛选的筛选方法和试剂盒在选定的培养基上固定一定量的选择的硫酸葡糖胺聚糖（SGAG），然后将一定量的所选择的淀粉样蛋白治疗候选物加入到一定量的溶解的低纤维Aβ1-40（LFAbeta）中 产生一个测试溶液，然后在培养基上加入一定量的测试溶液中的固定化SGAG以测试抑制，或者通过将一定量的选择的硫酸糖胺聚糖（SGAG）或GAG- 然后加入选定量的溶解的低纤维Abeta 1-40（LFAbeta），然后向培养基上的淀粉样蛋白斑添加选定量的所选淀粉样蛋白治疗候选物的测试溶液，以测试 中断